| Document |
Document Title |
|
WO/2021/162633A1 |
Disclosed herein is a process for the manufacture of a cationic fused N-heterocyclic ring system, comprising reaction of a compound of formula (I): with a base and with a material FF or only with a base to provide a compound of formula (...
|
|
WO/2021/151922A1 |
The invention relates to benzimidazole derivatives which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
|
|
WO/2021/153665A1 |
The present invention provides a compound that has an inhibitory effect on DYRK and that is represented by general formula (I) (in the formula, Q, R1, R2, and R3 are as defined in the description).
|
|
WO/2021/147879A1 |
The present invention relates to a compound represented by formula I as an inhibitor of Src homology region 2-containing protein tyrosine phosphatase-2 (SHP-2), a pharmaceutical composition, a preparation method, and a use thereof in tre...
|
|
WO/2021/145368A1 |
[Problem] The present invention addresses the problem of developing a photocatalyst compound that is capable of efficiently oxygenating amyloids in a low aggregation state and at a low concentration and that could reduce cytotoxicity und...
|
|
WO/2021/143680A1 |
The present invention relates to a heteroaryl derivative, a preparation method therefor, and an application thereof in medicine. Specifically, the present invention relates to a heteroaryl derivative as represented by general formula (AI...
|
|
WO/2021/141682A1 |
In accordance with the present disclosure, macrocyclic compounds of formula (I) have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vit...
|
|
WO/2021/142145A1 |
A compound of the formula (I): G1-L-G2, or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein G1 is a folate radical, an antifolate radical, or a folate analog radical; L is a linker; and G2 is ...
|
|
WO/2021/141041A1 |
Provided is a therapeutic agent and/or prophylactic agent for tauopathies that is based on the activation of voltage-gated sodium channels (Nav). The therapeutic agent and/or prophylactic agent for tauopathies has an Nav activator as an ...
|
|
WO/2021/132895A1 |
Provided is a benzazole derivative which effectively absorbs a high-energy external light source in the UV region and thus minimizes damage to organic materials in an organic electroluminescent device, thereby contributing to a substanti...
|
|
WO/2021/133915A1 |
Provided herein are small molecule modulators of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
|
|
WO/2021/129602A1 |
A substituted polycyclic compound and a pharmaceutical composition and use thereof. The substituted polycyclic compound is as shown in formula (I), wherein the definition of each group is detailed in the description. The present inventio...
|
|
WO/2021/122744A1 |
The present invention relates to the chemical synthesis of amanin and its derivatives. The present invention also relates to intermediate products of the amanin synthesis.
|
|
WO/2021/127404A1 |
A compound of Formula (I) is provided: (I) where the variables are defined herein.
|
|
WO/2021/123291A1 |
The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of ...
|
|
WO/2021/125474A1 |
Edoxaban p-toluenesulfonate monohydrate that is currently on the market has problems of having very poor crystallinity, being unstable due to moisture, being a pale yellow solid in terms of solid color, and being not easy to tablet durin...
|
|
WO/2021/118171A1 |
The present invention relates to a novel compound and an organic electronic device using same, and, more particularly, to a novel non-fullerene acceptor and an organic solar cell including same, the acceptor introducing an aryloxy- or he...
|
|
WO/2021/117846A1 |
The purpose of the present invention is to provide a compound having an inhibitory activity against a PDGF receptor kinase.　The present invention includes, for example, a compound represented by formula [1] or a pharmaceutically accept...
|
|
WO/2021/113679A1 |
The present disclosure relates to dimeric STING agonists of Formulae (I), (II), (III), (IV), (V), and (VI), and pharmaceutically acceptable salts thereof. The present disclosure also relates to methods of preparing the compounds and meth...
|
|
WO/2021/110169A1 |
Provided are a thiazololactam compound, and the use thereof in the preparation of a drug for treating ERK-related diseases. Specially, the present invention provides a compound as shown in formula (III) or a pharmaceutically acceptable s...
|
|
WO/2021/110890A1 |
Compounds of the formula (I) (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as herbicides.
|
|
WO/2021/113368A1 |
This disclosure is directed, at least in part, to SSTR5 antagonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the SSTR5 antagonists are gut-restricted compounds. In some embodi...
|
|
WO/2021/110656A1 |
The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of ...
|
|
WO/2021/107125A1 |
The present invention addresses the problem of providing a pharmaceutical having, as an active ingredient, a compound having agonistic activity on LPA3. As a result of having performed thoroughgoing studies, the inventors perfected the p...
|
|
WO/2021/108408A1 |
The present disclosure provides compounds useful for the inhibition of Delta-5 Desaturase ("D5D"). The compounds have a general Formula (I) wherein the variables of Formula (I) are defined herein. This disclosure also provides pharmaceut...
|
|
WO/2021/105334A1 |
The present invention provides novel compounds which bind to cereblon, and methods of use thereof. The compounds are represented by Formulas (I) and (II), below: (I) wherein Rx is selected from (Ia), (Ib), (Ic) and (Id); (II) wherein Ry ...
|
|
WO/2021/108254A1 |
The present disclosure provides methods for preparing MCL1 inhibitors or a salt thereof and related key intermediates.
|
|
WO/2021/100942A1 |
The present invention relates to a thienothiazolecarboxamide derivative, an enantiomer, diastereomer or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition enabling treatment of bacterial infection, especially tu...
|
|
WO/2021/102143A1 |
In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodula...
|
|
WO/2021/098593A1 |
The present invention relates to the technical field of natural medicine, and specifically relates to acquiring Secoemestrin C from microorganisms, particularly from fungal fermentation products, and the use of pharmaceutical salts there...
|
|
WO/2021/093860A1 |
Disclosed are a substituted bis-tricyclic compound, and a pharmaceutical composition and a use thereof. The substituted bis-tricyclic compound is as shown in formula (I); and the compound has an inhibitory effect on viruses and can be us...
|
|
WO/2021/093817A1 |
Disclosed are a class of amide compounds having novel structures or stereoisomers thereof or stereoisomer mixtures thereof and pharmaceutically acceptable salts thereof, and application thereof in the preparation of drugs for the treatme...
|
|
WO/2021/096860A1 |
The present disclosure generally relates to compounds of Formula (I) and pharmaceutical compositions that may be used in methods of treating cancer.
|
|
WO/2021/094312A1 |
The present invention relates to O-GIcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of ...
|
|
WO/2021/088787A1 |
Disclosed is a quinazoline compound used as an AXL inhibitor. The structure of the quinazoline compound is as shown in general formula (I), and the definition of each substituent is as described in the description. Further provided is a ...
|
|
WO/2021/088957A1 |
Disclosed are a novel aromatic heterocyclic compound as an ATX (Autotaxin) inhibitor, a pharmaceutical composition containing the compound, and a use of the compound and the composition in treatment of a disease having a pathological cha...
|
|
WO/2021/088945A1 |
The present invention falls within the field of medical chemistry and relates to a class of compounds as SHP2 inhibitors and the use thereof. Specifically, the present invention provides a compound represented by formula (I), or an isome...
|
|
WO/2021/089032A1 |
Disclosed are a compound as represented by general formula (I), a cis-trans isomer thereof, an enantiomer thereof, a diastereoisomer thereof, a racemate thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt...
|
|
WO/2021/082901A1 |
Provided are a phenylisoxazoline compound and use thereof. The phenylisoxazoline compound is represented by general formula (I). The compound of general formula (I) has good herbicidal activity, and can effectively control barnyard grass...
|
|
WO/2021/078120A1 |
Provided herein are a compound of formula (Ia) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, solid forms, combinations of pharmacologically active agents, pharmaceutical composi...
|
|
WO/2021/078141A1 |
The present invention discloses a novel purine derivative represented by formula (I) or a pharmaceutically acceptable salt thereof, intermediate and application thereof in preparation of a medicament for treating or preventing a cancer. ...
|
|
WO/2021/073456A1 |
Provided are a class of macrocyclic and cage-like molecules based on a biphenylarene and derivative compounds, a synthesis method therefor and the use thereof. A series of new macrocycles and molecular cages are obtained in a high yield ...
|
|
WO/2021/063404A1 |
A biaryl compound. Specifically disclosed is a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
|
|
WO/2021/066873A1 |
The disclosure includes compounds of Formula (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1 Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating a ...
|
|
WO/2021/062549A1 |
The present disclosure relates to redox active materials, such as the compound of formula (I), comprising at least one 2,5-dithio-7- azabicyclo(2.2. l)heptane unit connected to a surface thereof, as well as processes for making said redo...
|
|
WO/2021/067521A1 |
The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical composit...
|
|
WO/2021/067827A1 |
The present disclosure provides compounds, such as compounds of Formula I, and compositions that are MCL1 inhibitors.
|
|
WO/2021/062318A1 |
Provided herein are compounds of Formula (I) and Formula (II) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical composition...
|
|
WO/2021/048342A1 |
The present invention relates to the following compounds wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.
|
|
WO/2021/050994A1 |
Provided herein are heterobicyclic cyclopropanecarboxamide and heterobicyclic carboxamide compounds. In particular, provided herein are compounds that affect the function of kinases in a cell, and that are useful as therapeutic agents or...
|
